Uncomplicating Diabetes: Reducing the Burden of Diabetes-Related End-Organ Injury
joint with Vascular Biology and Human Diseases: From Molecular Pathways to Novel Therapeutics
Organizer(s): Mark E. Cooper, Thomas M. Coffman, Matthias G. von Herrath and Susan QuagginDate: February 25 - March 01, 2018
Location: Eldorado Hotel & Spa, Santa Fe, NM, USA
This Keystone Symposia conference will address diabetic complications which remain the major cause of morbidity and mortality in the diabetic population. Although the outlook has improved over the last two decades with respect to diabetic vascular disease, these complications remain a major burden with the underlying explanation for these complications at a molecular and cellular level as yet not fully clarified. With recent advances in the management of diabetes, particularly new classes of glucose-lowering agents, it is critical to determine if these new therapies have both glucose-dependent and independent effects in reducing diabetes-related end-organ injury. With major advances in our understanding of key pathological features of diabetic complications such as angiogenesis, fibrosis, inflammation and vascular remodeling, albeit in non-diabetic contexts, now is the time to translate this new knowledge to the field of diabetic complications. By learning from and recruiting such researchers into the field of diabetic complications, there is a great opportunity to develop novel, highly innovative approaches to identify new targets in order to discover new ways to treat, reverse or prevent diabetic complications that lead to premature atherosclerosis, heart failure, blindness, cognitive impairment and end-stage renal disease.
Scholarship Deadline: November 16 2017
Discounted Abstract Deadline: November 16 2017
Abstract Deadline: November 28 2017
Discounted Registration Deadline: December 20 2017
We gratefully acknowledge additional support for this conference from:
Diabetic Complications Consortium
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1 R13 DK116595-01
Funding for this conference was made possible (in part) by 1 R13 DK116595-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.